Security Snapshot

Wave Life Sciences Ltd. - COMMON STOCK (WVE) Institutional Ownership

CUSIP: Y95308105

13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

216

Shares (Excl. Options)

182,758,448

Price

$17.00

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / COMMON STOCK
Symbol
WVE on Nasdaq
Shares outstanding
185,455,765
Price per share
$7.18
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
182,758,448
Total reported value
$3,108,286,136
% of total 13F portfolios
0%
Share change
+19,905,556
Value change
+$421,681,039
Number of holders
216
Price from insider filings
$7.18
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • WVE - Wave Life Sciences Ltd. - COMMON STOCK is tracked under CUSIP Y95308105.
  • 216 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 216 to 73 between Q4 2025 and Q1 2026.
  • Reported value moved from $3,108,286,136 to $90,172,549.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 216 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP Y95308105?
CUSIP Y95308105 identifies WVE - Wave Life Sciences Ltd. - COMMON STOCK in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Wave Life Sciences Ltd. - COMMON STOCK (WVE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 17% -2.2% $248,138,341 34,225,506 0% RA Capital Management, L.P. 15 Apr 2026
Adage Capital Management, L.P. 5.4% -43% $139,157,787 -$74,376,843 9,786,061 -35% Adage Capital Management, L.P. 31 Dec 2025
BlackRock, Inc. 6.1% $63,555,507 9,360,163 BlackRock, Inc. 31 Dec 2024
MAVERICK CAPITAL LTD 5.4% $56,093,833 8,261,242 Maverick Capital, Ltd. 31 Dec 2024
FMR LLC 2.8% -63% $37,284,027 -$70,566,627 5,192,761 -65% FMR LLC 31 Mar 2026

As of 31 Dec 2025, 216 institutional investors reported holding 182,758,448 shares of Wave Life Sciences Ltd. - COMMON STOCK (WVE). This represents 99% of the company’s total 185,455,765 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Wave Life Sciences Ltd. - COMMON STOCK (WVE) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GSK plc 9.8% 18,245,691 0% 39% $310,176,747
RA CAPITAL MANAGEMENT, L.P. 9.8% 18,203,009 +0.01% 3.2% $309,451,153
FMR LLC 8.2% 15,135,983 +195% 0.01% $257,311,705
BlackRock, Inc. 6.8% 12,648,907 +21% 0% $215,031,419
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.3% 9,786,061 -33% 0.25% $166,363,037
MAVERICK CAPITAL LTD 5% 9,280,237 +11% 1.7% $157,764,029
PRICE T ROWE ASSOCIATES INC /MD/ 4% 7,407,372 +83% 0.01% $125,927,000
Darwin Global Management, Ltd. 3.9% 7,298,421 2.5% $125,167,920
Driehaus Capital Management LLC 3.5% 6,581,067 +4.5% 0.76% $111,878,139
M28 Capital Management LP 3.1% 5,664,548 0% 70% $96,297,316
FEDERATED HERMES, INC. 2.6% 4,744,520 +26% 0.13% $80,656,840
PRIMECAP MANAGEMENT CO/CA/ 2.2% 4,095,282 +116% 0.05% $69,619,794
683 Capital Management, LLC 2.2% 4,015,000 -3.3% 5.7% $68,255,000
VANGUARD GROUP INC 1.9% 3,573,746 +14% 0% $60,753,682
GEODE CAPITAL MANAGEMENT, LLC 1.7% 3,170,110 +8.6% 0% $53,902,133
STATE STREET CORP 1.6% 2,996,084 +5.3% 0% $50,933,428
GOLDMAN SACHS GROUP INC 1.5% 2,854,082 +34% 0.01% $48,519,394
Affinity Asset Advisors, LLC 1.5% 2,700,000 +29% 3.3% $45,900,000
EMERALD ADVISERS, LLC 1.3% 2,455,089 -18% 1.3% $41,736,513
Siren, L.L.C. 1.3% 2,450,000 -34% 1.2% $41,650,000
Kynam Capital Management, LP 1.2% 2,169,105 -52% 2.4% $36,874,785
LOOMIS SAYLES & CO L P 1.1% 2,040,223 -30% 0.04% $34,683,791
Pfizer Inc 1% 1,875,000 0% 13% $31,875,000
First Light Asset Management, LLC 1% 1,853,851 2.4% $31,515,467
Bellevue Group AG 0.8% 1,490,518 -64% 0.48% $25,338,806

Institutional Holders of Wave Life Sciences Ltd. - COMMON STOCK (WVE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 12,455,123 $90,172,549 -$3,765,935 $7.25 73
2025 Q4 182,758,448 $3,108,286,136 +$421,681,039 $17.00 216
2025 Q3 143,680,189 $1,051,640,675 +$37,184,597 $7.32 187
2025 Q2 138,939,054 $903,136,388 +$46,387,682 $6.50 174
2025 Q1 131,293,097 $1,061,209,645 +$20,316,471 $8.08 192
2024 Q4 128,616,529 $1,591,015,441 +$86,595,360 $12.37 181
2024 Q3 120,246,621 $986,101,781 +$176,011,863 $8.20 160
2024 Q2 95,071,148 $474,405,111 +$9,854,270 $4.99 143
2024 Q1 92,759,614 $572,308,103 +$4,033,614 $6.17 131
2023 Q4 92,528,153 $468,029,084 +$93,144,169 $5.05 115
2023 Q3 72,598,087 $417,436,128 +$3,006,886 $5.75 85
2023 Q2 72,147,137 $262,614,478 +$6,429,830 $3.64 80
2023 Q1 70,086,593 $303,466,627 +$3,780,454 $4.33 72
2022 Q4 68,108,089 $476,736,473 +$7,420,705 $7.00 74
2022 Q3 67,256,615 $242,816,542 -$1,613,831 $3.61 58
2022 Q2 67,784,074 $220,297,785 +$69,127,143 $3.25 56
2022 Q1 47,551,964 $95,097,268 -$1,035,989 $2.00 77
2021 Q4 47,284,486 $148,479,513 +$13,347,500 $3.14 87
2021 Q3 37,428,616 $183,549,240 +$443,975 $4.90 84
2021 Q2 37,041,603 $246,689,021 -$5,849,970 $6.66 82
2021 Q1 38,281,847 $214,782,368 +$1,495,724 $5.61 97
2020 Q4 36,092,793 $284,070,815 -$9,567,182 $7.87 102
2020 Q3 37,117,728 $315,928,313 +$59,335,508 $8.49 106
2020 Q2 29,422,263 $306,287,769 -$6,711,423 $10.41 89
2020 Q1 30,100,828 $282,072,986 +$9,439,494 $9.37 76
2019 Q4 29,498,551 $236,424,963 -$44,351,424 $8.01 87
2019 Q3 30,879,604 $633,634,840 +$1,025,937 $20.53 86
2019 Q2 30,470,000 $794,421,079 +$39,569,951 $26.09 100
2019 Q1 29,400,279 $1,142,135,791 +$191,634,667 $38.85 109
2018 Q4 24,393,021 $1,025,484,934 +$23,061,213 $42.04 91
2018 Q3 23,803,148 $1,190,156,500 -$29,678,796 $50.00 92
2018 Q2 24,465,339 $935,797,108 +$30,300,014 $38.25 77
2018 Q1 23,663,816 $948,860,012 +$61,087,976 $40.10 79
2017 Q4 22,225,342 $780,113,100 +$59,933,498 $35.10 72
2017 Q3 20,492,602 $445,796,252 +$26,521,810 $21.75 58
2017 Q2 19,316,233 $359,305,882 +$66,970,759 $18.60 55
2017 Q1 15,709,867 $431,755,770 +$32,771,317 $27.50 49
2016 Q4 14,822,157 $388,292,611 +$18,199,344 $26.15 51
2016 Q3 14,061,056 $456,556,375 -$3,399,325 $32.47 45
2016 Q2 14,199,612 $293,778,139 +$6,802,315 $20.69 37
2016 Q1 14,000,592 $192,282,000 +$2,926,211 $13.88 22
2015 Q4 13,788,837 $218,726,000 +$196,226,000 $15.95 18
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .